• 262
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2014  |  Volume : 9  |  Issue : 2  |  Page : 79-84

Bioequivalence comparison of generic drug DuLocap and brand drug Cymbalta

Department of Quality Assurnace and Regulatory Affairs, L. J. Institute of Pharmacy, Ahmedabad, Gujarat, India

Correspondence Address:
M Mudaliar
L. J. Institute of Pharmacy, Near Nagdev Kalyan Temple, Sanand Sarkhej Cross Roads, Ahmedabad 388 210, Gujarat
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/9783-1230.139169

Rights and Permissions

Abbreviated new drug application is required to submit to United States Food and Drug Administration for approval of the generic version of an innovator drug. This application is for (DuLocap) ® duloxetine hydrochloride delayed release (DR) capsules 60 mg manufactured by alpha pharmaceuticals. This application is an abridged application claiming essential similarity to the brand product that is, Cymbalta ® (duloxetine HCL DR capsules) 60 mg, mfg by Lily S.A, Spain and marketed by Eli Lilly, This is application is filed on the basis of para III (patent expires on June 11, 2013).

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded355    
    Comments [Add]    

Recommend this journal